Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Wipfler-Freissmuth, E; Loock, J; Moosig, F; Dejaco, C; Duftner, C; Schirmer, M.
Current therapeutic options for giant cell arteritis
Z Rheumatol. 2009; 68(2): 132-136.
Doi: 10.1007/s00393-008-0378-2
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Dejaco Christian
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Giant cell arteritis is the most common systemic vasculitis and affects large and medium-sized vessels. Glucocorticoids are the current standard in the therapy of giant cell arteritis. To reduce the glucocorticoid dose the European League Against Rheumatism (EULAR) suggests the addition of disease-modifying antirheumatic drugs. Of these, methotrexate represents the best investigated drug; possible alternatives include azathioprine, tumor necrosis factor-alpha inhibitors and cyclophosphamide.
- Find related publications in this database (using NLM MeSH Indexing)
- Anti-Inflammatory Agents - administration and dosage
- Antirheumatic Agents - administration and dosage
- Giant Cell Arteritis - drug therapy
- Glucocorticoids - administration and dosage
- Humans -
- Rheumatology - trends
- Find related publications in this database (Keywords)
- Giant cell arteritis
- Therapy
- Methotrexate
- TNF-alpha inhibitors
- Vasculitis